Sense Relief

Votes: 11
Views: 2490

Sense Relief Inc. Executive Summary
Using Apple Watch to Improve Management of Pregnancy-Related Nausea and Vomiting


Sense Relief App is a digital therapeutics software (DTx) that uses Apple Watch technology to deliver acupressure for fast and safe nausea relief, with an initial focus on pregnancy-related nausea and vomiting (PRNV). The Apple Watch is already the most widely used health wearable, with over 37% market share, and its Taptic Engine is capable of delivering acupressure to the P6 nerve on the inner wrist on demand. Collecting user data from the Apple Watch biosensors and Apple Health Records will allow for improved monitoring and predictive potential for patients suffering from PRNV, and additional maternal health issues such as preeclampsia and preterm labor.


Sense Relief App is the only antiemetic DTx, and the first software to use the Apple Watch to deliver a therapy. We will collect and analyze up to 27 different health signals and metrics from pregnant women using the Sense Relief App, to optimize the delivery of acupressure therapy in intensity, waveform, and duration. Then we will apply predictive analytics and program the Sense Relief App to deliver therapy sessions before symptoms occur. While most PRNV subsides in the second trimester, we will continue to record data, ideally through delivery, and use more advanced machine learning techniques to find insights into other maternal health issues, such as pregnancy-related hypertension/preeclampsia and preterm labor.


Sense Relief App is available on the Apple App Store, and over 200 active users have found nausea relief. While the mechanism by which acupressure helps is unclear, it is widely considered to be safe and without side effects and has been shown to be effective in 16 randomized controlled trials. The Sense Relief App has demonstrated in small uncontrolled sample size, that The Apple Watch Taptic Engine is capable of effectively delivering acupressure to P6 acupoint to relieve symptoms of nausea and vomiting.


PRNV is one of the most common complaints of pregnant women and is challenging to treat due to the desire to avoid potentially harmful medications during gestation. It affects nearly 3.5 million women in the US annually and can be so severe that 1% require hospitalization, accounting for over 10% of all non-delivery antenatal admissions. Up to 20% of women continue experiencing PRNV or “morning sickness” beyond the first trimester and has an indirect cost of over $1.7 billion. There are 4 million pregnancies in the United States every year, and maternal health costs $98 billion annually. The potential is to apply predictive analytics, derived from real-time health signals during maternity, will help improve PRNV management, and potentially lead to early detection of preeclampsia and pre-term births, which accounts for a $30.1 billion opportunity for health costs savings.



Voting is closed!


  • Name:
    Matt Bucklin
  • Type of entry:
    Team members:
    Matt Bucklin
    Adrienne Cheetham
    Moshe Zilversmit
    Sid Sinha
    Andrei Akaikine
    Patrick Ruane
  • Profession:
    Business Owner/Manager
  • Matt is inspired by:
    I am inspired by the potential for wearable technologies and digital therapeutics to bring down healthcare costs and improve peoples' health and lives.
    The Sense Relief team comprises a group of medical device, pharmaceutical, and medical entrepreneurs and experts. The company was started by a group of friends whose partners had all suffered severe PRNV. Realizing there was no effective solution, this team created Sense Relief to provide a safe, effective, and practical solution for the millions of women suffering from PRNV and millions more suffering from other causes of nausea and vomiting.
    To date, Sense Relief Inc. is self-funded by the founding team. Self-funding has covered the expenses of programming and App development, database hosting, launching the App on the Apple Store, acquiring over 200 active users, and strong IP protection.
  • Software used for this entry:
    X Code
  • Patent status: